Post-Market Monitoring Can Fill Innovative Switch Data Gaps – Consultants
This article was originally published in The Tan Sheet
Executive Summary
Allowing for post-market monitoring would incentivize sponsors to consider switches and generate data that could inform a decision about potential conditions for safe use “without applying potentially burdensome – and possibly unnecessary – conditions upfront,” Pinney Associates health care consultancy says.
You may also be interested in...
FDA Sketches NSURE Novel Switch Initiative In 2012
FDA clarified parameters for novel switches, including protecting innovators from potentially unfair generic competition and stating that a behind-the-counter class is not being considered, but the year ended without clear signals on what could be the potential first novel switch candidate and when FDA expects to propose regulatory changes to facilitate switches under conditions of safe use.
FDA Sketches NSURE Novel Switch Initiative In 2012
FDA clarified parameters for novel switches, including protecting innovators from potentially unfair generic competition and stating that a behind-the-counter class is not being considered, but the year ended without clear signals on what could be the potential first novel switch candidate and when FDA expects to propose regulatory changes to facilitate switches under conditions of safe use.
European OTC Switch Still Muted By Regulatory Resistance
OTC sales growth is stifled by the EU’s “extremely restricted” switch evaluation process, says AESGP Director General Hubertus Cranz. But while prescription revenues shrink as governments tighten budgets, the OTC market is not hampered in this way.